drugset
drugset / Trial / NCT04781634

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

NCT04781634 ↗

Phase 1/2 Recruiting 40 enrolled Chongqing Precision Biotech Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL

Timeline

Start
2021-03-07
Primary completion
2026-12-31
Completion
2027-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 and CD22 targeted prime CAR-T cells Cell therapy — Intravenous

Indications

No indication recorded.